PAD - Prescribing Advisory Database
PLEASE NOTE : This is a development system.

For Surrey PAD, please go to https://surreyccg.res-systems.net/PAD.

You are here : Home > PAD Profile : Mycophenolate mofetil - Oral disease indications

PAD Profile : Mycophenolate mofetil - Oral disease indications Important

Keywords :
Behcet's disease, refractory inflammatory oral disease, mycophenolic sodium, mycophenolic acid, RMOC, national shared care
Brand Names Include :
Arzip, CellCept, Myfortic, Myfenax, Ceptava
Important Information :
Prescribe generically (except in transplant indications)

Traffic Light Status

Status 1 of 1.

Status :
Amber
Formulations :
  • Capsules
  • Oral suspension
  • Tablets
Trust Alignment :
Primary Care
ASPH
RSFT
SASH
SABP
Links :
BNF NICE SPC
Un
Comments :
No comments returned.
Documents :

Guidelines

No guidelines returned.

Other Drugs

Other Indications

Additional Documents

Committee Recommendations

Date
Committee Name
Narrative
07 December 2022
Surrey & North West Sussex Area Prescribing Committee (formerly Prescribing Clinical Network)

The Surrey Heartlands Integrated Care System Area Prescribing Committee (APC) has agreed the National Shared Care Protocol (with local adaptations) for mycophenolate mofetil and mycophenolic acid for patients within adult services (non-transplant indications)

Associated BNF Codes

08. Malignant Disease and Immunosuppression
08.02.01. Antiproliferative immunosuppressants
This site uses its own and third party cookies to function properly and to improve performance, to maintain the session and to personalise user experience, as well as to obtain anonymous statistics about the use of the website. Visit our Privacy and Cookie Policy for more information on our data collection practices. By clicking 'Accept' you agree to our use of cookies for the purposes listed.
Learn More